Neogenomics (NEO) Current Assets (2010 - 2026)

Neogenomics (NEO) has 17 years of Current Assets data on file, last reported at $381.5 million in Q2 2026.

• Quarterly Current Assets fell 2.82% year-over-year to $381.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $381.5 million (down 2.82% YoY) and the FY2025 annual result came in at $376.3 million, down 36.87% from the prior year.
• Current Assets rose to $381.5 million in Q2 2026, from $373.7 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $651.1 million in Q1 2022 to a low of $373.7 million in Q1 2026.
• A 5-year average of $536.7 million and a median of $584.9 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2024 — Current Assets grew 0.56% — and 2025, when it tumbled 36.87%.
• Tracing NEO's Current Assets over 5 years: stood at $605.3 million in 2022, then declined by 1.4% to $596.8 million in 2023, then declined by 0.13% to $596.0 million in 2024, then plunged by 36.87% to $376.3 million in 2025, then gained by 1.38% to $381.5 million in 2026.
• The last three Current Assets figures came in at $381.5 million (Q2 2026), $373.7 million (Q1 2026), and $376.3 million (Q4 2025), per Business Quant data.